In the ever-evolving healthcare landscape of the United-States of America, strategic advice on pricing and reimbursement is paramount for pharma, biotech and medtech businesses aiming to thrive. As a global consulting agency, our firm specializes in offering expert guidance to companies navigating the intricate market entry processes in the US. With a team of specialists and consultants, we stand as a trusted partner for businesses seeking to understand the multi-payer environment of the USA including private payers, government-funded programs Medicare and Medicaid and players such as Pharmacy Benefit Managers. Our international team of experts is dedicated to ensuring you leverage of the pricing & reimbursement pathways in the United States. Trust in our consulting agency to be your guide in this dynamic market.
DEVELOPING PRICING & REIMBURSEMENT STRATEGIES FOR MEDICINES, MEDICAL DEVICES AND E-HEALTH
To successfully provide sustainable access to a new medicine or medical device, it is essential to have a robust pricing & reimbursement strategy that maximizes profits and/or access. An understanding of the Pricing & Reimbursement opportunities, willingness to pay, international reference pricing implications, and value drivers for payers, key opinion leaders, and other decision-makers is crucial to inform the pricing strategy and launch sequence.
Decision-makers’ needs and expectations vary across markets, and tailored approaches by a proficient consulting agency are needed to provide solutions meeting their needs. At Justin Stindt Consultants, a renowned consulting firm, we have experience designing hundreds of successful pricing & reimbursement strategies for medicines and medical devices in different therapeutic areas, and we strongly believe our team of experts can also help you achieve the best possible results for your market access.
Decentralized Dynamics: The US Healthcare Market’s Unique Position in Pricing & Reimbursement Pathways
The Unique Landscape of US Healthcare Spending and Drug Pricing
The United-States of America stands out as a leader in health spending, allocating a substantial 17.8% of its GDP to healthcare in 2021. This figure significantly surpasses the OECD average of 9.6%, making the US the top spender on healthcare among OECD countries. However, unlike many other countries that implement price controls to regulate drug prices, the USA adopts a fully decentralized approach to pricing and reimbursement offering a unique environment for pharma, biotech and medtech companies and our consulting agency.
This means that there are no federal-level price controls or centralized organizations overseeing drug pricing, allowing manufacturers to have greater autonomy in setting their drug prices. However, some provisions of the recent Inflation Reduction Act represent a step in the opposite direction.
Market Dynamics and Pricing Freedom: Understanding the US’s Position as the Global Leader in Drug Prices
The lack of price controls has contributed to the US having a reputation for being the friendliest for pricing and reimbursement in the world and for having the highest drug prices globally in many therapy areas. Drug list prices in the US often exceed the prices that manufacturers can achieve in other countries. The absence of cost-effectiveness criteria and national added benefit assessments, common in many European countries, further adds to the flexibility of pricing in the United-States.
EXPLORING THE HEALTHCARE SPENDING LANDSCAPE IN THE UNITED STATES
The majority of people in the US participate in a private insurance plan with the two main government-sponsored options, Medicare and Medicaid, mainly dedicated to specific parts of the American population. Medicare primarily covers people aged 65 or older and Medicaid serves primarily as a health insurance option for children and for people with lower incomes or disabilities who qualify for coverage.
In the US, the pricing and reimbursement landscape is characterized by direct negotiations between manufacturers and insurers. With a diverse range of private and public healthcare coverage options available, manufacturers negotiate individually with payers, rather than adhering to pricing limits set by a single governing body. Pharmacy benefit managers (PBMs) are effectively middlemen within the health insurance system, negotiating with manufacturers to secure lower drug prices. Specialty products are often assessed by Specialty Pharmacy Managers (SPMs).
Challenges and opportunities in the us healthcare system
While the US healthcare system offers numerous opportunities for pharmaceutical companies to operate within a free-pricing market, it also poses unique challenges that our consulting agency can help you meet. For example, while free pricing exists, it does not guarantee automatic reimbursement. Payers independently assess drugs based on their expectations. As a result, payers utilize various tools to control pricing and coverage, including formulary lists, prior authorization requirements, step edits, quantity limits, and national drug code (NDC) blocks. These cost-containment measures can limit access and may involve little manufacturer input. However, contracting negotiations can help to alleviate these measures, e.g. securing a more favorable tier placement on the formulary in exchange for a discount on the price.
The Institute for Clinical and Economic Review (ICER) plays a significant role in drug pricing assessments in the US. As an independent watchdog, ICER’s evaluations carry considerable weight, shaping payer decisions. For more information on this or Academy of Managed Care Pharmacy (AMCP) dossiers visit our P&R dossiers – US page.
Justin Stindt ConsultantS, a renowned expert consulting agency, provides strategic advice on pricing & reimbursement pathways in the US.
At Justin Stindt Consultants, we recognize the intricacies of pricing and reimbursement in the dynamic US healthcare landscape. Our team of experts in strategic pricing advice and market access empowers pharmaceutical companies to navigate these unique challenges effectively. With a deep understanding of the decentralized system and direct negotiations between manufacturers and insurers and PBMs / SPMs, we provide tailored solutions to optimize pricing strategies while ensuring patients’ access to life-changing therapies. For some products, there are special pathways, e.g., some therapeutics may be assessed by radiology benefit managers.
As the healthcare landscape continues to evolve, our consultants stay at the forefront of the latest developments, enabling us to offer proactive and innovative approaches to pricing and reimbursement pathways in the US. Our commitment to fostering innovation and promoting equitable access makes us the ideal consulting agency & partner to address the complexities of the US market.
Contact us today to learn more about our services and how we can support your company in achieving pricing excellence and maximizing patient impact. Together, let’s make a significant difference in improving patient access to vital medications in the United States and beyond.
Our consulting agency offers a strategic assessment of the Pricing & Reimbursement pathways for your asset in the U.S. This will include an overview of the available pathways and specific recommendations which pathway would be optimal for your asset.
If you want to determine the price potential of your product, our consulting agency develops Pricing & Reimbursement strategies.
If you have any questions on Pricing & Reimbursement pathways – US and for support in identifying the optimal pathways for your asset, please contact one of our consultants.
Meet one of our Strategic advice on Pricing & Reimbursement Pathways US experts
Get in touch with our expert
CLIENT TESTIMONIALS
